Skip to NavigationSkip to content

takeovers

Mirror. Signal. Merger. How to deal with a pharma takeover

Published on 14/12/15 at 10:29am

So 2015 has been a record year for M&A in the pharma industry.

The Financial Times has called this “the most vigorous period of M&A among drug makers since the turn of the century”. And, as if to emphasise the point, Pfizer have just completed the staggeringly large $160 billion takeover of Allergan, the maker of Botox.

Five benefits and challenges of the Pfizer/Allergan mega-merger

Published on 07/12/15 at 10:26am
Pfizer CEO Ian Read
Pfizer chief executive Ian Read will remain at the helm of the new company - for now

Pfizer was extremely keen to get the $160 billion deal done, but what is it getting out of the acquisition, and what are the risks?

Positives

Tax inversion

Controversial or not, moving its tax domicile from the US to Ireland is expected to allow Pfizer to cut its tax bill from around 26% to 17 or 18%. This should free up significant funds for investment into the business.

Growth boost

2015's top five mergers and acquisitions in a record-breaking year

Published on 19/10/15 at 02:19pm
The takeover of Allergan by Teva is the top pharma M&A deal so far in 2015
Allergan

A new report from analysts MergerMarket reveals that mergers and acquisitions so far in 2015 have surpassed the same 2014 period in value for the pharma healthcare industry.

M&A activity in global pharma, medical and biotech in 2015 reached 954 transactions, worth $367.6 billion. Although this is a lower number of transactions compared to the 980 seen in the same period in 2014, the total value increased by 46.2%, from $251.5bn, driven largely by a surge of M&A activity within the pharma sub-sector

Depomed rejects Horizon’s latest takeover bid

Depomed has rejected Horizon Pharma’s latest bid, stating the proposal is ‘inadequate’ and ’undervalues’ the company.

The Irish pharma company offered a $33 per share proposal, up from its previous $29.25 per share offer valued at approximately $2.0 billion.

Pharma dominates global M&A activity

Flickr/TaxRebate.org.uk

Mergers and acquisitions in the pharma, medical and biotech sectors have hit the highest levels in nearly 15 years, a new industry report has found.

Figures compiled by industry analysts the Mergermarket group show global mergers and acquisitions in the pharma, medical and biotech sectors hit the highest half-year value on record since the first half of 2001.

M&A drama continues as Mylan rejects Teva

Teva has been accused of trying to distract its rival Mylan

Mylan has firmly rejected Teva’s acquisition bid, even though its own bid for Irish firm Perrigo has also been turned down.

Teva made an offer to buy the US generics firm for around $40 billion last week, in a move that would create the world’s largest generic company

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches